Key result
Beta-blocker treatment in heart failure patients improved left ventricular ejection fraction across various agents, with mean increases ranging from 4.6 to 8.6 EF units.
Why the study?
Does the improvement in ejection fraction differ among various beta-blockers in patients with heart failure?
Population
Patients with heart failure and left ventricular dysfunction from 43 studies.
Comparison
Beta-blocker treatment vs Comparison among different beta-blockers and…
Design
Meta-analysis
Follow-up
4 to 9.5 months (mean follow-up varied by drug)
Authors
Loading...
Any beta-blocker improves LVEF similarly in HF; confirms survival differences arise from non-EF mechanisms.
Systematic Review
Does the improvement in ejection fraction differ among various beta-blockers in patients with heart failure?
Beta-blocker therapy consistently improves ejection fraction in heart failure regardless of the specific agent, suggesting that observed survival differences between agents are driven by mechanisms other than LV function improvement.
CAMPEN et al. (1998) conducted a systematic review in Heart failure with left ventricular dysfunction. Beta-blockers (metoprolol, carvedilol, bucindolol, nebivolol, atenolol, propranolol) vs. Various beta-blockers and etiologies compared against each other was evaluated on Improvement in ejection fraction (EF). Beta-blocker treatment in heart failure patients improved left ventricular ejection fraction across various agents, with mean increases ranging from 4.6 to 8.6 EF units.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: